Alto Neuroscience, Inc.

What they do

Alto operates a proprietary Precision Psychiatry Platform that integrates neurocognitive assessments, EEG, wearables, and genetic data, using machine learning to identify brain-based biomarkers. The company's pipeline consists of seven clinical-stage assets across major depressive disorder, bipolar depression, treatment-resistant depression, schizophrenia, and Parkinson's disease. Its lead program, ALTO-207, is a fixed-dose combination of pramipexole and ondansetron in development for treatment-resistant depression. As a clinical-stage company, Alto has no commercial products and has funded operations primarily through equity financings.

Revenue drivers

• Product revenue — None. The company has no approved products and reports no product revenue; all pipeline assets remain clinical-stage.
• ALTO-207 (pramipexole/ondansetron, TRD) — Most advanced program and primary value driver. A potentially registrational Phase 2b adjunctive trial began in April 2026, with an adjunctive Phase 3 planned by early 2027 and a monotherapy Phase 3 planned for 2H 2027.
• ALTO-300 (agomelatine) — Investigational oral small molecule described in the 10-K and 10-Q pipeline; no revenue and no disclosed pivotal-stage timeline in the provided excerpts.
• Other pipeline assets and Platform — Seven clinical-stage assets in total across MDD, BPD, TRD, schizophrenia, and Parkinson's disease. The Platform is described as commercially scalable but has generated no revenue to date.

Recent performance

Alto reported a net loss of $63.2 million for 2025, versus $61.4 million in 2024 and $36.3 million in 2023, with diluted EPS of $-2.19 in 2025. Operating cash flow was $-51.8 million in 2025, compared with $-47.4 million in 2024. As of June 30, 2026, the company reported total assets of $254.1 million, total liabilities of $34.8 million, shareholders' equity of $219.2 million, cash and equivalents of $243.7 million, and long-term debt of $12.4 million. In its August 12, 2026 earnings release, Alto said it completed an approximately $100 million financing in July 2026, resulting in pro forma cash of approximately $338 million and expected runway through 2030.

Strategy

Alto's stated strategy is to build a leading precision psychiatry company by using its Platform to advance the first biomarker-driven pipeline for neuropsychiatric indications. It is prioritizing ALTO-207 across both adjunctive and monotherapy treatment-resistant depression settings under the PACE program. The company expects to initiate an adjunctive Phase 3 trial by early 2027 after FDA alignment and a monotherapy Phase 3 trial in the second half of 2027, alongside the ongoing Phase 2b trial. It cited a July 2026 approximately $100 million financing as funding planned operations through 2030. Management also highlights biomarker work, including a 2025 prospectively replicated EEG biomarker associated with larger placebo response in MDD.

Risks

• No revenue and recurring losses — Alto has no history of commercializing products and has incurred substantial losses since inception, with net losses of $36.3 million in 2023, $61.4 million in 2024, and $63.2 million in 2025.
• Need for additional capital — The 10-K states the company will require substantial additional financing, and failure to obtain capital on acceptable terms could force it to delay, limit, reduce, or terminate development or commercialization efforts.
• Clinical development uncertainty — Preclinical and clinical development is lengthy, expensive, and uncertain, and earlier study results may not be predictive of future trial results for programs such as ALTO-207 and ALTO-300.
• Dependence on Platform biomarkers — The 10-K states Alto relies heavily on biomarker data gathered from its Platform and anticipates that certain therapeutic candidates will require development of biomarkers, so failure of the Platform to reproducibly predict treatment outcomes would undermine the pipeline.

Outlook

Management expects topline data from the ALTO-207 Phase 2b trial in treatment-resistant depression in the second half of 2027. It expects to initiate an adjunctive Phase 3 trial by early 2027 following Phase 3 readiness work and FDA alignment, and a monotherapy Phase 3 trial in the second half of 2027. The company says pro forma cash of approximately $338 million, reflecting the July 2026 approximately $100 million financing, is expected to fund planned operations through 2030. No revenue guidance was provided.